

WEST**End of Result Set**
 [Generate Collection](#) [Print](#)

L6: Entry 2 of 2

File: USPT

May 29, 2001

US-PAT-NO: 6238917

DOCUMENT-IDENTIFIER: US 6238917 B1

TITLE: Asymmetric hammerhead ribozymes

DATE-ISSUED: May 29, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hendry; Philip	Leichhardt			AUX
McCall; Maxine J.	Putney			AUX

ASSIGNEE-INFORMATION:

NAME	CITY	STATE ZIP CODE	COUNTRY TYPE CODE
Commonwealth Scientific Industrial Research Organization	Dickson		AUX 03

APPL-NO: 9/ 156828 [PALM]

DATE FILED: September 18, 1998

PARENT-CASE:

This application is a continuation of PCT International Application No. PCT/AU97/00210, filed Apr. 2, 1997, designating the United States of America which is a continuation-in-part of U.S. patent application Ser. No. 08/627,033, filed Apr. 2, 1996 now abandoned.

INT-CL: [7] A61 K 31/708, A61 K 31/712, C07 H 21/00, C12 N 5/10, C12 Q 1/68

US-CL-ISSUED: 435/325; 435/6, 435/9131, 435/375, 536/243, 536/2431, 536/2432, 536/245
 US-CL-CURRENT: 435/325; 435/375, 435/6, 435/91.31, 536/24.3, 536/24.31, 536/24.32,
536/24.5

FIELD-OF-SEARCH: 435/6, 435/91.31, 435/375, 435/325, 435/358, 435/365, 435/419,
 435/252.3, 435/252.33, 435/254.2, 514/44, 536/24.5, 536/24.3, 536/24.31, 536/24.32

PRIOR-ART-DISCLOSED:

U.S. PATENT DOCUMENTS

 [Search Selected](#) [Search ALL](#)

PAT-NO	ISSUE-DATE	PATENTEE-NAME	US-CL
<u>5149796</u>	September 1992	Rossi et al.	536/232
<u>5254678</u>	October 1993	Haseloff et al.	536/232
<u>5334711</u>	August 1994	Sproat	536/245

FOREIGN PATENT DOCUMENTS

FOREIGN-PAT-NO	PUBN-DATE	COUNTRY	US-CL
93/23057	November 1993	WOX	
93/23569	November 1993	WOX	

OTHER PUBLICATIONS

Denman et al. "Different activity of trans-acting hammerhead ribozymes targeted to β -amyloid peptide precursor mRNA by altering the symmetry of helices I and III" Arch. Biochem. Biophys. 323 (1): 71-78, Oct. 20, 1995.

ART-UNIT: 165

PRIMARY-EXAMINER: Schwartzman, Robert A.

ASSISTANT-EXAMINER: Larson, Thomas G.

ATTY-AGENT-FIRM: White, John P. Cooper & Dunham LLP

ABSTRACT:

This invention is directed to a compound having the formula: ##STR1##

as defined in the detailed description. The compound may be covalently linked to a delivery agent. The invention also includes a composition which comprises the compound in association with an acceptable carrier. The invention also includes a method of cleaving an RNA target sequence which comprises contacting a target sequence with the compound as described above. Further, a method of treating a disease in man or animals associated with a particular RNA which comprises administrating to the man or animal the compound. Further, the invention also includes a diagnostic reagent which comprises the compound.

18 Claims, 7 Drawing figures